Moderna (NASDAQ: MRNA) is now far below its peak market cap last summer of nearly $200 billion. In this Motley Fool Live video recorded on Jan. 5, Fool contributors Keith Speights and Brian Orelli discuss how low Moderna needs to go to make the stock a clear bargain. Keith Speights: Now, another company has already been a huge winner with COVID-19 and I'm talking about Moderna.
Dr. Andre Campbell, a professor of surgery at UCSF and ICU physician at Zuckerberg San Francisco General Hospital, joins Yahoo Finance Live to discuss the rise in COVID-19 cases in California, staffing shortages, and the need to vaccinate as many Americans as possible.
Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.